TD Cowen Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $15
Research Alert: CFRA Keeps Sell View On Shares Organon & Co
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $15
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating, Announces Target Price $11
Express News | Organon & Co : BofA Global Research Cuts Price Objective to $11 From $15
BofA Securities Adjusts Price Target on Organon to $11 From $15, Maintains Underperform Rating
Cautious Hold Rating on Organon Amid Updated Financials and Market Conditions
OgaLong collaborates with multiple retail partners to jointly promote the scientific management of gout throughout its entire cycle.
On the occasion of World Gout Day on April 20, the global leading healthcare company Ogalon, in collaboration with the well-known chain pharmacy Gaoji Health and the online medication platform Meituan Buy Medicine, calls for the integration of retail health management advantages of SSE Select Resources Industries Index, extending the full-chain health management for gout patients from hospitals to outside hospitals, providing patients with more "accessible" Professional Services. This call not only responds to the national policy direction for refined management of chronic diseases but also embodies the collaborative efforts to enhance the level of grassroots medical services.
Express News | Organon Appoints Ramona a. Sequeira to the Company’s Board of Directors
Organon Appoints Ramona A. Sequeira to the Company's Board of Directors
Press Release: Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
Express News | Organon & Co - Expects $6 Million Milestone Expense in Q1 2025
Organon Reports Health Canada Approves NDUVRA, 1%, For The Topical Treatment Of Plaque Psoriasis In Adults
Express News | Health Canada Approves Nduvra™ (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
The Market Doesn't Like What It Sees From Organon & Co.'s (NYSE:OGN) Earnings Yet As Shares Tumble 27%
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $15
Organon & Is Maintained at Equal-Weight by Morgan Stanley
Organon Analyst Ratings
Express News | Organon & Co. : Morgan Stanley Cuts Target Price to $15.00 From $16.00